INCEPTA PHARMA
INCEPTA PHARMACEUTICALS LTD.
🏢 Company Background
Founded in 1999,
2nd largest pharma in Bangladesh,
#1 among 7 Tirzepatide manufacturers
Two major plants: Savar & Dhamrai
Covers 97% of local medical needs
Exported to 74 countries in 2025
2nd largest pharma in Bangladesh,
#1 among 7 Tirzepatide manufacturers
Two major plants: Savar & Dhamrai
Covers 97% of local medical needs
Exported to 74 countries in 2025
🔬 Technical Strength
Certified by EU GMP & UK MHRA
Operating 783 product lines
Pioneered 158 new drugs in Bangladesh
Flagship products: Osimertinib 9291 (lung cancer), Tirzema (Tirzepatide), etc.
Operating 783 product lines
Pioneered 158 new drugs in Bangladesh
Flagship products: Osimertinib 9291 (lung cancer), Tirzema (Tirzepatide), etc.
📊 Industry Position
Market share in Bangladesh: 10.2%
28 strategic warehouses nationwide
#1 in international certifications among Bangladesh pharma
Oncology drug exports: Global TOP 10
28 strategic warehouses nationwide
#1 in international certifications among Bangladesh pharma
Oncology drug exports: Global TOP 10
Website: www.inceptaphrama.com
Product
Image
Image
Tirzema®
(Tirzepatide & Tirzepatide Injection)
❤️ Core Information
- Generic name: Tirzepatide Injection
- Strengths: 2.5mg/0.5ml, 5mg/0.5ml, 7.5mg/0.5ml
- Shelf life: 24 months (Store 2–8°C)
- Indications: Type 2 Diabetes & Obesity Treatment
🏆 Product Advantages
- Dual GLP-1/GIP receptor agonist
- Once-weekly subcutaneous injection
- Clinical weight loss up to 22.5%
- HbA1c reduction of 2.3%